Skip to main content
Top
Published in: Journal of Ophthalmic Inflammation and Infection 1/2013

Open Access 01-12-2013 | Original research

Candida dubliniensis endophthalmitis: five cases over 15 years

Authors: Thomas P Moloney, Joseph Park

Published in: Journal of Ophthalmic Inflammation and Infection | Issue 1/2013

Login to get access

Abstract

Background

Recent studies have shown that the recently identified organism Candida dubliniensis is less pathogenic than the more common Candida albicans. Due to its rare nature, C. dubliniensis has been previously reported as the causative organism in endophthalmitis in only three cases. We undertook a multicenter, retrospective, consecutive case series to describe the clinical features and outcomes of patients with culture-proven C. dubliniensis endophthalmitis. Medical records were reviewed for all patients with C. dubliniensis endophthalmitis on vitreous/aqueous cultures from June 1998 to June 2013 from all public hospitals throughout Queensland, Australia.

Results

Six eyes from five patients were identified - four males and one female aged from 21 to 55 years (mean 37 years). Four patients were intravenous drug users and four patients had hepatitis C. All five patients were treated with systemic antifungal therapy and intravitreal antifungal injections, and all required vitrectomy. Two eyes developed retinal detachment over the course of the endophthalmitis. Five eyes had visual outcomes of 20/60 or better, and one eye had a poor outcome with final visual acuity of hand movements only. There was no associated mortality, and no infected eyes required enucleation or evisceration.

Conclusions

C. dubliniensis endophthalmitis is a rare condition which occurs mainly in intravenous drug users and can occur in both HIV-positive and HIV-negative patients. Unlike C. albicans endophthalmitis, C. dubliniensis endophthalmitis has reasonable visual outcomes and does not appear to be associated with high mortality.
Literature
1.
go back to reference Walsh TJ: Emerging fungal pathogens: evolving challenges to immunocompromised patients. In Emerging infections 1, chap 15. Edited by: Scheld WM, Armstrong D, Hughes JM. ASM Press, Washington, DC; 1998. Walsh TJ: Emerging fungal pathogens: evolving challenges to immunocompromised patients. In Emerging infections 1, chap 15. Edited by: Scheld WM, Armstrong D, Hughes JM. ASM Press, Washington, DC; 1998.
2.
go back to reference Sullivan DJ, Westerneng TJ, Haynes KA, Bennett DE, Coleman DC: Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. Microbiology 1995, 141: 1507–1521. 10.1099/13500872-141-7-1507PubMedCrossRef Sullivan DJ, Westerneng TJ, Haynes KA, Bennett DE, Coleman DC: Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. Microbiology 1995, 141: 1507–1521. 10.1099/13500872-141-7-1507PubMedCrossRef
3.
go back to reference Gutierrez J, Morales P, Gonzalez M, Quidos G: Candida dubliniensis, a new fungal pathogen. J Basic Microbiol 2002, 42: 207–227. 10.1002/1521-4028(200206)42:3<207::AID-JOBM207>3.0.CO;2-CPubMedCrossRef Gutierrez J, Morales P, Gonzalez M, Quidos G: Candida dubliniensis, a new fungal pathogen. J Basic Microbiol 2002, 42: 207–227. 10.1002/1521-4028(200206)42:3<207::AID-JOBM207>3.0.CO;2-CPubMedCrossRef
5.
go back to reference Pelegrin L, Mesquida M, Adan A, Cervera C, Bosch-Mestres J, Esteban-Redondo C, Juiz-Gonzalez P, Llorenc V, Miro JM: Candida dubliniensis endophthalmitis in a HIV-infected intravenous drug abuser. Mycoses 2010, 54: e856-e858.CrossRef Pelegrin L, Mesquida M, Adan A, Cervera C, Bosch-Mestres J, Esteban-Redondo C, Juiz-Gonzalez P, Llorenc V, Miro JM: Candida dubliniensis endophthalmitis in a HIV-infected intravenous drug abuser. Mycoses 2010, 54: e856-e858.CrossRef
6.
go back to reference Espinosa-Heidmann DG, McMillan BD, Rocco Lasala P, Stanley J, Larzo CR: Candida dubliniensis endophthalmitis: first case in North America. Int Ophthalmol 2012, 32: 41–45. 10.1007/s10792-011-9499-8PubMedCrossRef Espinosa-Heidmann DG, McMillan BD, Rocco Lasala P, Stanley J, Larzo CR: Candida dubliniensis endophthalmitis: first case in North America. Int Ophthalmol 2012, 32: 41–45. 10.1007/s10792-011-9499-8PubMedCrossRef
7.
go back to reference Sullivan DJ, Moran GP, Pinjon E, Al-Mosaid A, Stokes C, Vaughan C, Coleman DC: Comparison of the epidemiology, drug resistance mechanisms, and virulence of Candida dubliniensis and Candida albicans. FEMS Yeast Res 2004, 4: 369–376. 10.1016/S1567-1356(03)00240-XPubMedCrossRef Sullivan DJ, Moran GP, Pinjon E, Al-Mosaid A, Stokes C, Vaughan C, Coleman DC: Comparison of the epidemiology, drug resistance mechanisms, and virulence of Candida dubliniensis and Candida albicans. FEMS Yeast Res 2004, 4: 369–376. 10.1016/S1567-1356(03)00240-XPubMedCrossRef
8.
go back to reference Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, Kauffman CA, Hyslop N, Mangino JE, Chapman S, Horowitz HW, Edwards JE, Dismukes WE, NIAID Mycoses Study Group: A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003, 37: 634–643. 10.1086/376906PubMedCrossRef Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, Kauffman CA, Hyslop N, Mangino JE, Chapman S, Horowitz HW, Edwards JE, Dismukes WE, NIAID Mycoses Study Group: A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003, 37: 634–643. 10.1086/376906PubMedCrossRef
9.
go back to reference Menezes AV, Sigesmund DA, Demajo WA, Devenyi RG: Mortality of hospitalized patients with Candida endopthalmitis. Arch Intern Med 1994, 154: 2093–2097. 10.1001/archinte.1994.00420180103012PubMedCrossRef Menezes AV, Sigesmund DA, Demajo WA, Devenyi RG: Mortality of hospitalized patients with Candida endopthalmitis. Arch Intern Med 1994, 154: 2093–2097. 10.1001/archinte.1994.00420180103012PubMedCrossRef
10.
go back to reference Meis JF, Ruhnke M, De Pauw BE, Odds FC, Siegert W, Verweij PE: Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation. Emerg Infect Dis 1999, 5: 150–153. 10.3201/eid0501.990119PubMedCentralPubMedCrossRef Meis JF, Ruhnke M, De Pauw BE, Odds FC, Siegert W, Verweij PE: Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation. Emerg Infect Dis 1999, 5: 150–153. 10.3201/eid0501.990119PubMedCentralPubMedCrossRef
11.
go back to reference Brandt ME, Harrison LH, Pass M, Sofair AN, Huie S, Li RK, Morrison CJ, Warnock DW, Hajjeh RA: Candida dubliniensis fungemia: the first four cases in North America. Emerg Infect Dis 2000, 6: 46–49. 10.3201/eid0601.000108PubMedCentralPubMedCrossRef Brandt ME, Harrison LH, Pass M, Sofair AN, Huie S, Li RK, Morrison CJ, Warnock DW, Hajjeh RA: Candida dubliniensis fungemia: the first four cases in North America. Emerg Infect Dis 2000, 6: 46–49. 10.3201/eid0601.000108PubMedCentralPubMedCrossRef
12.
go back to reference Sebti A, Kiehn TE, Perlin D, Chaturvedi V, Wong M, Doney A, Park S, Sepkowitz KA: Candida dubliniensis at a cancer center. Clin Infect Dis 2001, 32: 1034–1038. 10.1086/319599PubMedCrossRef Sebti A, Kiehn TE, Perlin D, Chaturvedi V, Wong M, Doney A, Park S, Sepkowitz KA: Candida dubliniensis at a cancer center. Clin Infect Dis 2001, 32: 1034–1038. 10.1086/319599PubMedCrossRef
13.
go back to reference Odds FC, Van Nuffel L, Dams G: Prevalence of Candida dubliniensis isolates in a yeast stock collection. J Clin Microbiol 1998, 36: 2869–2873.PubMedCentralPubMed Odds FC, Van Nuffel L, Dams G: Prevalence of Candida dubliniensis isolates in a yeast stock collection. J Clin Microbiol 1998, 36: 2869–2873.PubMedCentralPubMed
14.
go back to reference Jabra-Rizk MA, Baqui AAMA, Kelley JI, Falkler WA Jr, Merz WG, Meiller TF: Identification of Candida dubliniensis in a prospective study of patients in the United States. J Clin Microbiol 1999, 37: 321–326.PubMedCentralPubMed Jabra-Rizk MA, Baqui AAMA, Kelley JI, Falkler WA Jr, Merz WG, Meiller TF: Identification of Candida dubliniensis in a prospective study of patients in the United States. J Clin Microbiol 1999, 37: 321–326.PubMedCentralPubMed
15.
go back to reference Jabra-Rizk MA, Falkler WA Jr, Merz WG, Baqui AAMA, Kelley JI, Meiller TF: Retrospective identification and characterization of Candida dubliniensis isolates among Candida albicans clinical laboratory isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected individuals. J Clin Microbiol 2000, 38: 423–2426. Jabra-Rizk MA, Falkler WA Jr, Merz WG, Baqui AAMA, Kelley JI, Meiller TF: Retrospective identification and characterization of Candida dubliniensis isolates among Candida albicans clinical laboratory isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected individuals. J Clin Microbiol 2000, 38: 423–2426.
16.
go back to reference Sallam A, Taylor SRJ, Khan A, McCluskey P, Lynn WA, Manku K, Pacheco PA, Lightman S: Factors determining visual outcome in endogenous Candida endophthalmitis. Retina 2012, 32: 1129–1134. 10.1097/IAE.0b013e31822d3a34PubMedCrossRef Sallam A, Taylor SRJ, Khan A, McCluskey P, Lynn WA, Manku K, Pacheco PA, Lightman S: Factors determining visual outcome in endogenous Candida endophthalmitis. Retina 2012, 32: 1129–1134. 10.1097/IAE.0b013e31822d3a34PubMedCrossRef
17.
go back to reference Coleman DC, Moran GP, McManus BA, Sullivan DJ: Mechanisms of antifungal drug resistance in Candida dubliniensis. Future Med 2010, 5: 935–949.CrossRef Coleman DC, Moran GP, McManus BA, Sullivan DJ: Mechanisms of antifungal drug resistance in Candida dubliniensis. Future Med 2010, 5: 935–949.CrossRef
18.
go back to reference Moran GP, Coleman DC, Sullivan DJ: Candida albicans versus Candida dubliniensis: why is C. albicans more pathogenic? Int J Microbiol 2012, 2012: 205921.PubMedCentralPubMedCrossRef Moran GP, Coleman DC, Sullivan DJ: Candida albicans versus Candida dubliniensis: why is C. albicans more pathogenic? Int J Microbiol 2012, 2012: 205921.PubMedCentralPubMedCrossRef
Metadata
Title
Candida dubliniensis endophthalmitis: five cases over 15 years
Authors
Thomas P Moloney
Joseph Park
Publication date
01-12-2013
Publisher
Springer Berlin Heidelberg
Published in
Journal of Ophthalmic Inflammation and Infection / Issue 1/2013
Electronic ISSN: 1869-5760
DOI
https://doi.org/10.1186/1869-5760-3-66

Other articles of this Issue 1/2013

Journal of Ophthalmic Inflammation and Infection 1/2013 Go to the issue